Grail Inc (GRAL) Stock AnalysisGRALGrail Inc

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer. It operates in the Healthcare sector (MEDICAL LABORATORIES industry).

Grail Inc is a good buy right now due to its current price of $140.58, which is significantly below the average analyst price target of $150. Additionally, the RSI is at 62.35, suggesting the stock is not overbought, and there is potential for further gains as the Galleri test approaches FDA approval, which could drive revenue growth by 58% to $147 million by 2025. However, the main risk is the company's ongoing unprofitability, with a net income of -110 million in Q2 2026, which investors should consider before purchasing.